Institution
Chittaranjan National Cancer Institute
Healthcare•Kolkata, West Bengal, India•
About: Chittaranjan National Cancer Institute is a healthcare organization based out in Kolkata, West Bengal, India. It is known for research contribution in the topics: Cancer & Population. The organization has 571 authors who have published 923 publications receiving 19868 citations. The organization is also known as: Chittaranjan Cancer Hospital & CNCI, Kolkata.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: VILI had a significantly higher sensitivity than VIA in detecting HSIL, but specificity was similar, and appears to be a more accurate visual test for use in screening and treatment programs in low‐resource settings.
Abstract: Visual inspection-based screening tests, such as visual inspection with 4% acetic acid (VIA) and with Lugol's iodine (VILI), have been proposed as alternatives to cytology in mass screening programs. To date, there is only limited information on the accuracy of these tests in detecting High-grade Squamous Intraepithelial Lesions (HSIL). Eleven cross-sectional studies involving 56,939 women aged 25-65 years were conducted in Burkina Faso, Congo, Guinea, India, Mali and Niger to evaluate the accuracy of VIA and VILI performed by health workers. A common protocol and questionnaire was used. For final diagnosis, all women were investigated with colposcopy and biopsies were taken when necessary. Data from the studies were pooled to calculate sensitivity, specificity and predictive values of the tests for the detection of HSIL. Of the screened women, 16.1% and 16.4% were positive on examination using, respectively, VIA and VILI; 1,063 were diagnosed with HSIL. The pooled sensitivity, specificity, positive and negative predictive values for VIA were 76.8% (95% CI: 74.2-79.4%), 85.5% (95% CI: 85.2-85.8%), 9.4% (95% CI:8.8-10.8%) and 99.5% (95% CI:99.4-99.6%), respectively. The values were 91.7% (95% CI: 89.7-93.4%), 85.4% (95% CI: 85.1-85.7%), 10.9% (95% CI: 10.2-11.6%) and 99.8% (95% CI:99.7-99.9%), respectively for VILI. The range of sensitivity and specificity for VIA was 56.1-93.9% and 74.2-93.8%, respectively, between studies and were 76.0-97.0 % and 73.0-91.3% for VILI. VILI had a significantly higher sensitivity than VIA in detecting HSIL, but specificity was similar. VILI appears to be a more accurate visual test for use in screening and treatment programs in low-resource settings.
309 citations
••
TL;DR: Results reveal that in vivo damage or stimulation of specific central dopaminergic system suppresses or enhances functional activities of the immune effector cells.
298 citations
••
TL;DR: A major finding was the consistently higher sensitivity but equal specificity of VILI compared with VIA, and some caution is warranted in the interpretation of observed accuracy measures, since a certain degree of gold standard misclassification cannot be excluded.
Abstract: Cervical cancer is the main cancer among women in sub-Saharan Africa, India and other parts of the developing world. Evaluation of screening performance of effective, feasible and affordable early detection and management methods is a public health priority. Five screening methods, naked eye visual inspection of the cervix uteri after application of diluted acetic acid (VIA), or Lugol's iodine (VILI) or with a magnifying device (VIAM), the Pap smear and human papillomavirus testing with the high-risk probe of the Hybrid Capture-2 assay (HC2), were evaluated in 11 studies in India and Africa. More than 58,000 women, aged 25-64 years, were tested with 2-5 screening tests and outcome verification was done on all women independent of the screen test results. The outcome was presence or absence of cervical intraepithelial neoplasia (CIN) of different degrees or invasive cervical cancer. Verification was based on colposcopy and histological interpretation of colposcopy-directed biopsies. Negative colposcopy was accepted as a truly negative outcome. VIA showed a sensitivity of 79% (95% CI 73-85%) and 83% (95% CI 77-89%), and a specificity of 85% (95% CI 81-89%) and 84% (95% CI 80-88%) for the outcomes CIN2+ or CIN3+, respectively. VILI was on average 10% more sensitive and equally specific. VIAM showed similar results as VIA. The Pap smear showed lowest sensitivity, even at the lowest cutoff of atypical squamous cells of undetermined significance (57%; 95% CI 38-76%) for CIN2+ but the specificity was rather high (93%; 95% CI 89-97%). The HC2-assay showed a sensitivity for CIN2+ of 62% (95% CI 56-68%) and a specificity of 94% (95% CI 92-95%). Substantial interstudy variation was observed in the accuracy of the visual screening methods. Accuracy of visual methods and cytology increased over time, whereas performance of HC2 was constant. Results of visual tests and colposcopy were highly correlated. This study was the largest ever done that evaluates the cross-sectional accuracy of screening tests for cervical cancer precursors in developing countries. The merit of the study was that all screened subjects were submitted to confirmatory investigations avoiding to verification bias. A major finding was the consistently higher sensitivity but equal specificity of VILI compared with VIA. Nevertheless, some caution is warranted in the interpretation of observed accuracy measures, since a certain degree of gold standard misclassification cannot be excluded. Because of the correlation between visual screening tests and colposcopy and a certain degree of over-diagnosis of apparent CIN2+ by study pathologists, it is possible that both sensitivity and specificity of VIA and VILI were overestimated. Gold standard verification error could also explain the surprisingly low sensitivity of HC2, which contrasts with findings from other studies.
279 citations
••
TL;DR: The results suggest an immunoregulatory role of DA and targeting DA receptors and their signaling pathways in these cells by using DA receptor agonists and antagonists may be useful for the treatment of diseases where DA induced altered immunity play a pathogenic role.
Abstract: The neurotransmitter dopamine (DA) is an important molecule bridging the nervous and immune systems. DA through autocrine/paracrine manner modulates the functions of immune effector cells by acting through its receptors present in these cells. DA also has unique and opposite effects on T cell functions. Although DA activates naive or resting T cells, but it inhibits activated T cells. In addition, changes in the expression of DA receptors and their signaling pathways especially in T cells are associated with altered immune functions in disorders like schizophrenia and Parkinson's disease. These results suggest an immunoregulatory role of DA. Therefore, targeting DA receptors and their signaling pathways in these cells by using DA receptor agonists and antagonists may be useful for the treatment of diseases where DA induced altered immunity play a pathogenic role.
262 citations
••
TL;DR: The drug appears to act as a potent biological response modifier with antitumor and antiviral effect and antagonize in vitro the cytopathic effect of HIV.
Abstract: Mangiferin, a C-glucosylxanthone (1,3,6,7-tetrahydroxyxanthone-C2-β- D -glucoside) purified from plant sources was shown to have in vivo growth-inhibitory activity against ascitic fib
257 citations
Authors
Showing all 571 results
Name | H-index | Papers | Citations |
---|---|---|---|
Tapas Kumar Maji | 54 | 253 | 9804 |
Suman Chakraborty | 53 | 664 | 11769 |
Partha Basu | 32 | 147 | 2851 |
Debajyoti Choudhury | 31 | 128 | 3368 |
Paramita M. Ghosh | 30 | 101 | 3358 |
Chinmay Kumar Panda | 30 | 144 | 2521 |
Santanu Dasgupta | 29 | 79 | 3785 |
Sujit Basu | 26 | 48 | 2484 |
Jaydip Biswas | 26 | 127 | 2159 |
Nitya G. Chakraborty | 26 | 64 | 2222 |
Rathindranath Baral | 26 | 85 | 1983 |
Triparna Sen | 25 | 57 | 1709 |
Anamika Bose | 24 | 71 | 1534 |
Sudin Bhattacharya | 23 | 64 | 1298 |
Sukta Das | 23 | 48 | 1428 |